Association of PIV With Survival Outcomes in Patients With mRCC Treated With Nivolumab as Second-Line Therapy and Beyond
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study
J. Cancer Res. Clin. Oncol. 2022 May 26;[EPub Ahead of Print], E Yekedüz, D Tural, İ Ertürk, S Karakaya, C Erol, Ö Ercelep, Ç Arslan, ÖN Sever, S Kılıçkap, N Şentürk Öztaş, A Küçükarda, O Can, B Öksüzoğlu, MA Şendur, N Karadurmuş, Y ÜrünFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.